| Keryx Biopharmaceuticals Initiates Phase 3 Registration Program Of Zerenex (ferric Citrate) For The Treatment Of Patients With Hyperphosphatemia |
| Scritto da Urology/Nephrology News From Medical News Today |
 Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) announced the initiation of its short-term Phase 3 study of Zerenex? (ferric citrate), the Company's iron-based phosphate binder for the treatment of elevated serum phosphorous levels, or hyperphosphatemia, in patients with end-stage renal disease on dialysis...Fonte: Urology/Nephrology News From Medical News Today |